Gene Therapy Pricing: The Math Behind $3M Cures

A gene therapy costs $3 million for a single dose. Casgevy is $2.2 million. Elevidys is $3.2 million. Hemgenix is $3.5 million. Lenmeldy tops the chart at $4.25 million. Most investors assume this is pure greed. It is not. The price is a formula forced by the economics of one-time curative therapies treating tiny patient populations. If you cannot do the math, you cannot value the stock.

The solution: gene therapy pricing is patient population times treatment rate times price, minus R&D cost, minus the 90% of programs that fail. The $3 million tag is what the math demands. Here is how to run the numbers and why most gene therapy stocks are binary bets on whether payers will reimburse.

Step 1: Understand the price ladder

Gene therapies sit at the top of a pricing pyramid. Enzyme replacement therapies for rare diseases run $200,000 to $500,000 per year, every year, for life. Orphan drugs like Ionis zilganersen for Alexander disease price at $300,000 to $500,000 annually. The orphan drug pricing guide covers that tier in detail. Gene therapies are different: one dose, one time, $2 to $4.25 million.

The list prices are public. Vertex priced Casgevy (sickle cell disease) at $2.2 million. Sarepta priced Elevidys (Duchenne muscular dystrophy) at $3.2 million. CSL Behring priced Hemgenix (hemophilia B) at $3.5 million. Orchard Therapeutics priced Lenmeldy (metachromatic leukodystrophy) at $4.25 million, the most expensive drug in the world as of 2024. Bluebird bio priced Zynteglo (beta-thalassemia) at $2.8 million.

The justification is cost-offset pricing. Bluebird estimated that lifetime blood transfusions for a beta-thalassemia patient exceed $6 million. At $2.8 million one-time, Zynteglo is cheaper than the disease, if it works permanently. That “if” is where the investor risk lives.

Step 2: Learn why manufacturing sets the floor

AAV vector production is the bottleneck. The active ingredient in most in vivo gene therapies is an adeno-associated virus carrying a functional gene into the patient’s cells. Manufacturing AAV at scale is hard: low yields, capacity constraints, and batch-to-batch variability inherent to growing viruses in living cells. The AAV manufacturing market was $3.2 billion in 2026 and is projected to grow at 13.4% annually through 2035.

The cost per dose reflects this. Current AAV therapies cost $850,000 to $3.5 million per patient at list price. Industry estimates put the cost of goods for autologous CAR-T at roughly $95,000 per dose, and AAV vector manufacturing is even more capital-intensive. A 2025 Nature analysis found that indication-specific AAV production costs vary dramatically, with high-dose systemic therapies costing far more per dose than localized ones.

For comparison, a small molecule pill costs $0.10 to $1 per dose to manufacture. The manufacturing cost alone for a gene therapy can exceed the entire list price of a $1 billion-a-year pill. This is why gene therapy companies cannot simply “price lower.” The floor is set by the physics and biology of viral vector production. For more on the vectors themselves, see the AAV vs lentivirus guide. The FDA maintains a list of approved cellular and gene therapy products that shows every approved product to date.

Step 3: Do the patient population math

The revenue formula for a gene therapy is:

Diagnosed patients × treatment rate × price = peak revenue

Take Casgevy. The addressable market Vertex cites is more than 60,000 eligible patients across approved regions. At $2.2 million per patient, the total addressable market is $132 billion. But 18 months after approval, only 39 patients had been infused out of that 60,000-person market. The Casgevy 18-month commercial analysis shows why: apheresis, manufacturing, myeloablative conditioning chemotherapy, and treatment-center capacity throttle the funnel. Of 500 patients who initiated the treatment journey, only 39 were infused, a 7.8% conversion rate.

The treatment rate is the lever most investors overestimate. Realistic treatment rates for gene therapies run 1 to 5% of the addressable population in the first five years. For Casgevy, that means 600 to 3,000 patients, generating $1.3 billion to $6.6 billion in peak revenue over a 5 to 10 year ramp, not $132 billion on day one.

For Sarepta’s Elevidys, the $3.2 million price works only if payers believe the surrogate endpoint (dystrophin production) predicts clinical benefit. If the confirmatory trial fails and the FDA withdraws approval, revenue goes to zero regardless of price. See the accelerated approval guide for why reversal risk matters more for gene therapies.

Step 4: Factor in the R&D recovery problem

Gene therapy development costs $500 million to $1 billion per asset. Roughly 90% of gene therapy programs fail before approval, higher than the overall biotech failure rate. A company that brings one gene therapy to market has paid for the successes and the failures.

At 500 patients treated at $2.2 million, gross revenue is $1.1 billion. Subtract manufacturing costs ($500,000 to $1 million per dose), subtract the R&D cost of the approved drug, and subtract the R&D cost of the 2 to 3 failed programs that preceded it. The margin is thin.

Bluebird bio is the cautionary tale. The company priced Zynteglo at $2.8 million, offered an 80% refund if it didn’t work, and still could not secure reimbursement in Europe. After failing to reach agreements with German payers, bluebird withdrew Zynteglo from the market and wound down its European operations entirely. The price was right for the economics. It was wrong for the payers. By 2025, bluebird warned investors it was at risk of insolvency and laid off 30% of its workforce.

Step 5: Understand the payment infrastructure

The $3 million price is not paid upfront in most cases. CMS launched the Cell and Gene Therapy Access Model in January 2025, the first federal program to negotiate outcomes-based agreements with gene therapy manufacturers on behalf of state Medicaid agencies. As of 2026, 33 states plus DC and Puerto Rico participate. The model ties payment to outcomes: if the patient remains cured, the payer pays over time. If the therapy fails, the manufacturer issues rebates.

This means companies do not always recognize $2.2 million in revenue on infusion day. Under outcomes-based contracts, payment may flow over 3 to 5 years, contingent on the patient remaining disease-free. Vertex negotiated similar agreements for Casgevy with private payers. The revenue recognition lag is 12 to 24 months between infusion and full payment.

Step 6: Run the valuation formula

The investor framework for a gene therapy company is:

(Patient population × treatment rate × price) × probability of approval − R&D cost = risk-adjusted value

Use the rNPV method. For a full breakdown, see the biotech valuation guide. The key inputs for gene therapies: use a 10 to 13% discount rate (not 40%, because clinical risk goes in the probability weights, not the discount rate), a 5 to 10 year revenue ramp, and a cumulative probability of approval from Phase 3 of roughly 55 to 60%.

For Sarepta, the Elevidys revenue was $2.18 billion TTM as of mid-2026, but the stock traded at $15.43 with a $1.66 billion market cap, or 0.76x trailing revenue. The market is pricing in the label controversy, the high-dose AAV safety concerns (two patient deaths from acute liver failure in 2025), and the possibility that the confirmatory trial does not verify clinical benefit. The $3.2 million price works for the economics. Whether it works for the stock depends on whether the science holds up.

Common mistakes

• Modeling gene therapy revenue like a chronic drug. One-time curative pricing sounds large, but the treatment funnel throttles revenue. Casgevy at $2.2 million per patient generated $42.9 million in a quarter, roughly 20 patients.
• Assuming the list price equals revenue. Outcomes-based contracts delay payment. Revenue recognition can lag infusion by 12 to 24 months.
• Ignoring payer resistance. Bluebird bio priced Zynteglo correctly for the economics and still could not get European payers to reimburse. A correct price that no one pays is zero revenue.
• Forgetting manufacturing cost. AAV production at $500,000 to $1 million per dose means the gross margin on a $2.2 million therapy is not what most investors assume.
• Underestimating the failure rate. Roughly 90% of gene therapy programs fail. The approved drug pays for the failed ones.
• Using peak sales multiples without discounting for ramp. A gene therapy at $3 billion peak revenue in year 8 is not worth 3x $3 billion today. The 5 to 10 year ramp destroys present value at any discount rate.

Final checklist

• List price confirmed from company press release or FDA label
• Addressable patient population verified (diagnosed, not prevalence)
• Realistic treatment rate applied (1-5% in first 5 years)
• Manufacturing cost per dose estimated
• Outcomes-based payment lag modeled (12-24 months)
• R&D cost including failed programs factored in
• Revenue ramp set at 5-10 years (not 3-5)
• Probability of approval applied by development stage
• Comparable commercial outcomes checked (Casgevy uptake, Zynteglo withdrawal)